Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

June 02, 2015 3:04 PM ET


Company Overview of Iconic Therapeutics, Inc.

Company Overview

Iconic Therapeutics, Inc., a biopharmaceutical company, develops production and purification procedures for proteins that attack and destroy pathologic cells. It develops hI-con1, a recombinant protein that triggers immune cell-mediated killing of TF-expressing uterine serous papillary adenocarcinoma and clear cell ovarian cancer cells. The company was incorporated in 2002 and is based in Atlanta, Georgia.

127 Peachtree Street, N.E.

Suite 1551

Atlanta, GA 30303

United States

Founded in 2002





Key Executives for Iconic Therapeutics, Inc.

Chief Executive Officer
Co-Founder, President, Chief Financial Officer and Director
Chief Scientist and Scientific Advisor
Clinical Trials Advisor
Age: 52
Compensation as of Fiscal Year 2014.

Iconic Therapeutics, Inc. Key Developments

Iconic Therapeutics, Inc. Appoints K. Peter Hirth as Director and Senior Scientific Advisor

Iconic Therapeutics, Inc. announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director of the company and will work closely with Iconic's leadership team as a Senior Scientific Advisor. Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, and Afferent Pharmaceuticals. From 2001 to 2013 at Plexxikon, Dr. Hirth built a novel, structure-guided drug discovery platform, which brought several new chemical entities into the clinic, including Zelboraf, an FDA-approved therapy for metastatic melanoma together with a companion diagnostic. Prior to Sugen, he was Vice President of Research at Boehringer Mannheim where he successfully led the company's erythropoietin program to approval in 1989. Dr. Hirth was a research scientist with the Max Planck Institute. He completed his post-doctoral work at the University of California, San Diego and received his PhD in molecular genetics from Heidelberg University, Germany.

Iconic Therapeutics, Inc. Announces Management Appointments

Iconic Therapeutics, Inc. announced that MPM partner William Greene, MD, has joined the company as Chief Executive Officer. Additionally, MPM Managing Director Todd Foley, H.I.G. Managing Director Bruce Robertson, PhD, and Lundbeckfond Ventures Senior Partner Johan Kordel, PhD, have joined the Board of Directors. Prior to joining Iconic Therapeutics, Dr. Greene was a Managing Director at MPM Capital. Previously, he was a Senior Clinical Scientist at Genentech where he led the early clinical development of Lucentis for AMD.

Similar Private Companies By Industry

Company Name Region
BIO-IVT Group United States
Vesta Therapeutics, Inc. United States
EGWU, Inc. United States
Xoma (US) LLC United States
Cognate TiGenix United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Iconic Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at